The Patent Finder

Intelgenx Corp.

17 patents currently held · Updated Nov 19, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

1
Ending by 2030
Aug 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Oct 7 to 16, 2027 · next Oct 7

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,674,479Sustained-release bupropion and bupropion/mecamylamine tablets
In force
 · USPTO record
In forceUSPTO record
US 10,610,528Solid oral film dosage forms and methods for making same
In force
 · USPTO record
In forceUSPTO record
US 9,717,682Solid oral film dosage forms and methods for making same
In force
 · USPTO record
In forceUSPTO record
US 8,735,374Oral mucoadhesive dosage form
In force
 · USPTO record
In forceUSPTO record
US 10,272,038Film dosage form with extended release mucoadhesive particles
In force
 · USPTO record
In forceUSPTO record
US 11,957,785Film dosage form with extended release mucoadhesive particles
In force
 · USPTO record
In forceUSPTO record
US 12,653,780Method of Treatment and Device for the Improved Bioavailability of Leukotriene Receptor Antagonists
In force
 · Medium confidence
In forceMedium confidence
US 9,949,934Device and method of treating conditions associated with neuroinflammation
In force
 · USPTO record
In forceUSPTO record
US 10,722,476Device and method of treating conditions associated with neuroinflammation
In force
 · USPTO record
In forceUSPTO record
US 11,648,212Loxapine film oral dosage form
In force
 · USPTO record
In forceUSPTO record
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 2 abandoned · 23 no status recorded

Rows 11 to 27 of 27 are for members. The first 10 are on the company page.
Pro members see all 27 published applications.
Upgrade to Pro
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited